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Abstract
Aims/hypothesis The aim of the study was to determine the
transition rate and factors associated with the progression of
normo- and low microalbuminuria to diabetic nephropathy
(overt proteinuria).
Methods For 8 years we prospectively observed 1,558
Japanese patients with type 2 diabetes mellitus whose basal
urinary albumin:creatinine ratio (UACR) had been mea-
sured as <17.0 mg/mmol at entry. The incidence of
nephropathy (UACR >33.9 mg/mmol) was determined by
measuring UACR twice a year.
Results Progression to nephropathy occurred in 74 patients.
The annual transition rate was 0.67%, and was substantially
higher for the low-microalbuminuric group than for the
normoalbuminuric group (1.85% and 0.23%, respectively;
hazard ratio for the low-microalbuminuric group 8.45, p<
0.01). The hazard ratio for an HbA1c of 7–9% or ≥9% was
2.72 (p<0.01) or 5.81 (p<0.01) relative to HbA1c <7.0%,
respectively. In comparison with individuals with a systolic
blood pressure (SBP) of <120 mmHg, the hazard ratios for
patients with an SBP of 120–140 mmHg or ≥140 mmHg
were 2.31 (p= 0 . 0 6 )a n d3 . 5 4( p<0.01), respectively.
Smoking also affected progression to proteinuria (hazard
ratio 1.99, p<0.01). In contrast, 30.3% of the low-
microalbuminuric group returned to normoalbuminuria
(i.e. were in remission).
Conclusions/interpretation These results suggest that if
patients with type 2 diabetes mellitus are receiving
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DOI 10.1007/s00125-010-2025-0treatment from diabetologists for hyperglycaemia and
hypertension when they are in the early stages of
nephropathy (i.e. normo- or low microalbuminuria), their
rate of transition to proteinuria is considerably lowered, and
that differentiating patients with low microalbuminuria
from those with high microalbuminuria might be clinically
useful.
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Introduction
Diabetic nephropathy is the most common cause of end-
stage renal disease (ESRD) in many countries, including
Japan [1–3]. In the UK Prospective Diabetes Study
(UKPDS), 24.9% of patients developed microalbuminuria
within 10 years of diagnosis of type 2 diabetes, but only
0.8% developed ESRD, as assessed by an elevated plasma
creatinine level (>250 μmol/l) or the need for renal
replacement therapy [4]. Annual rates of transition between
successive stages within the classic paradigm of normoal-
buminuria to microalbuminuria to macroalbuminuria to
ESRD were 2–3% per year [4].
In Japan, the number of patients requiring renal
replacement therapy has increased threefold in less than
15 years [3]. Among 36,017 patients who started haemo-
dialysis in 2007, the number of diabetic patients has
reached 15,663 (43.5%) [3]. In Hong Kong, the overall
number of people receiving renal replacement therapy
increased by 50% between 1995 and 1999, and in the
diabetic group, a 100% increase was observed [5]. Thus,
Asians have a predisposition to diabetic nephropathy and
ESRD. In fact, the recent Japanese Incipient to Overt:
Angiotensin II Receptor Blocker, Telmisartan, Investigation
on Type 2 Diabetic Nephropathy (INNOVATION) trial
revealed that about 50% of diabetic individuals with high
microalbuminuria (urinary albumin/creatinine ratio [UACR]
between11.3and33.9mg/mmol[100–300mg/g])progressed
toproteinuriawithin2years[6], indicating that progression is
very rapid once high microalbuminuria develops. On the
other hand, intervention using angiotensin receptor blockers
(ARBs) such as losartan or telmisartan seems to be very
effective in Asians in comparison with Europeans [6, 7]. The
Japan Diabetes Complications Study (JDCS) is a nationwide
randomised controlled study of type 2 diabetic patients
focusing on lifestyle modification [8, 9]. Although the status
of control of most classic cardiovascular risk factors,
including body weight, glycaemia, serum lipids and blood
pressure, did not differ between the two groups during the
study period, the incidence of stroke in the intensive lifestyle
intervention group (0.55/100 patient-years) was significantly
lower than in the control group (0.95/100 patient-years) by
Kaplan–Meier analysis, while the incidence of nephropathy
did not differ significantly between the groups [9]. Here, we
report the rate of transition and factors associated with the
development and/or progression of normo- and low micro-
albuminuria to diabetic nephropathy (overt proteinuria) in
this JDCS cohort.
Methods
In 1996, 2,205 patients aged 40–70 years with previously
diagnosed type 2 diabetes and HbA1c levels of >6.5% were
recruited and registered from 59 hospitals specialising in
diabetes care. The protocol for the study, which was in
accordance with the Declaration of Helsinki and the Ethical
Guidelines for Clinical/Epidemiological Studies of the
Japanese Ministry of Health, Labour and Welfare, received
ethics approval from the institutional review boards of all
the participating institutions. Written informed consent was
obtained from all the patients enrolled. The inclusion
criteria for participating patients have been described
previously by Sone et al. [8]. A final total of 2,033 patients
aged 58.5±6.9 years (mean ± SD) were included in the
study, and their diabetes duration was 10.9±7.2 years.
The recruited patients were randomly allocated to either
an intensive lifestyle intervention group or a conventional
treatment group. Details of the intervention have been
described previously by Sone et al. [8, 9]. We selected a
cohort of 1,558 patients in whom the mean value of the
two-spot UACR was <17.0 mg/mmol (150 mg/g) without
microscopic haematuria or other clinical findings indicating
other renal diseases. We followed this cohort for 8 years,
and measured their body weight, waist/hip circumference
1026 Diabetologia (2011) 54:1025–1031and blood pressure at least twice a year. Fasting plasma
glucose, HbA1c, serum lipids and serum creatinine levels
were also determined twice a year. Spot UACR was also
determined at least twice a year using the turbidimetric
immunoassay to measure the urinary albumin concentration.
We defined normoalbuminuria as a UACR of <3.4 mg/mmol
(30 mg/g), and low microalbuminuria as a UACR of 3.4 to
17.0 mg/mmol (30 to 150 mg/g). Estimated glomerular
filtration rate (eGFR) was calculated using serum
creatinine levels according to the modification of diet in
renal disease (MDRD) formula modified for Japanese
populations [10].
Statistical analyses The primary endpoint for the nephrop-
athy analysis was transition from normo- or low micro-
albuminuria to proteinuria (>33.9 mg/mmol [300 mg/g]) in
two consecutive urine samples. Transition to proteinuria
was summarised by the annual rate of transition to
proteinuria and the remission proportion was defined as
those patients whose mean UACR at the final two visits
was <3.4 mg/mmol. Risk factors for proteinuria were
explored by the following survival analysis methods.
Univariate analyses were performed by the Kaplan–Meier
method, logrank test, and univariate Cox regression with
a 95% CI. Multivariate Cox regression was also used.
The SAS software package (version 9.2, SAS Institute,
Cary, NC, USA) was used for all analyses, with the level
of significance set at p<0.05.
Results
Tables 1 and 2 give the baseline characteristics and
glycaemic and blood pressure control at baseline, and at 4
and 8 years after the start of observation. As shown in
Table 2, the proportion of patients who were receiving
insulin injections increased from 20.7% to 41.9% over
8 years. The use of antihypertensive agents also increased
over this period from 28.2% to 42.0%. In particular, usage
of renin–angiotensin system inhibitors such as angiotensin-
converting enzyme (ACE) inhibitors and/or ARBs in-
creased from 12.3% to 28.4% over 8 years. The use of
statins also increased from 20.5% to 31.1%. Over a
median follow-up period of 7.98 years, 74 patients
developed proteinuria. The annual transition rate was
0.67 per 100 person-years (95% CI 0.53–0.84). For the
low-microalbuminuric group, the annual transition rate
per 100 person-years was substantially higher than for
the normoalbuminuric patients (1.85 [95% CI 1.43–2.41]
a n d0 . 2 3[ 9 5 %C I0 . 1 4 –0.36]), respectively. On the other
hand, remission (i.e. normalisation) occurred in 137
(30.3%) of the 452 individuals with low microalbumi-
nuria (Table 3).
Figure 1 shows the Kaplan–Meier curves for progression
to overt nephropathy on the basis of UACR (Fig. 1a), HbA1c
level (Fig. 1b), systolic blood pressure (SBP, Fig. 1c)a n d
smoking status (Fig. 1d). As can be seen, patients with
higher UACR, higher HbA1c, higher SBP or current smokers
had a higher risk for progression to proteinuria. The hazard
ratio for the low-microalbuminuric group was 8.45 (p<0.01)
relative to the normoalbuminuric group. Stratification of
eGFR to >90, 60–90 and <60 ml min
–1 1.73 m
–2 did not
predict progression to proteinuria. The hazard ratio of HbA1c
for a range of 7–9% or for ≥9% was 2.72 (p<0.01) or 5.81
(p<0.01) relative to an HbA1c of <7%, respectively. In
comparison with individuals with an SBP of <120 mmHg,
the hazard ratio for patients with an SBP of 120–140 mmHg
or ≥140 mmHg was 2.31 (p=0.06) and 3.54 (p<0.01),
respectively. Smoking also affected progression to protein-
uria, with a hazard ratio of 1.99 (p<0.01).
Table 4 shows risk factors for the development of
proteinuria based on multivariate Cox regression analysis.
All the factors shown to be significant by univariate
analysis—UACR, HbA1c level, SBP level and smoking
status—were significantly associated with the development
of proteinuria after adjustment for other clinical factors.
Multivariate Cox regression analysis showed that the
hazard ratio for use of ACE inhibitors and/or ARBs was
1.49 (95% CI 0.83–2.69, p=0.19) and that the hazard ratio
for use of statins was 0.73 (95% CI 0.38–1.41, p=0.35) in
relation to the progression to proteinuria.
Table 1 Baseline characteristics of 1,558 patients included in the
nephropathy analysis
Variable Mean ± SD
a
n (men/women) 1,558 (813/745)
Age (years) 58.5±6.9
BMI (kg/m
2) 23.0±2.9
Waist (cm) 79.4±9.2
SBP (mmHg) 132.4±15.8
DBP (mmHg) 76.6±9.5
Fasting plasma glucose (mmol/l) 8.9±2.4
HbA1c (%) 7.8±1.3
Duration of diabetes (years) 10.7±7.1
Serum total cholesterol (mmol/l) 5.19±0.89
Serum triacylglycerols (mmol/l)
b 1.15±0.82
Serum HDL-cholesterol (mmol/l) 1.41±0.43
UACR (mg/mmol)
b 1.8±3.0
eGFR (ml min
−1 1.73 m
−2)
b 81.3±32.1
Current/past/never smoker (%) 27/24/49
Ethanol intake: 0/1–38/≧38 g/day (%) 62/31/7
DBP, diastolic blood pressure
aUnless otherwise stated
bMedian±interquartile range
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Based on the main result of the JDCS study, which was
reported previously by Sone et al., the incidence of stroke
in the intensive lifestyle intervention group was significant-
ly lower, by 38%, than in the control group, while the
incidence of nephropathy did not differ significantly
between the groups [9]. Lifestyle intervention resulted in
a small but significant temporary improvement of glycae-
mic control and only minimal changes in other known risk
factors for diabetic complications, including blood pressure,
indicating the difficulty of changing the lifestyle of patients
with long-term diabetes. In this sense, patients who
participated in this study could be considered as represen-
tative of the general population of patients with type 2
diabetes. This might explain why there was no difference in
the incidence of diabetic nephropathy. The main finding of
interest in this study was that the annual incidence of
proteinuria was as low as 0.67% (0.67/100 person-years), in
marked contrast to previous reports. In the UKPDS, the
annual rates of transition from normoalbuminuria to micro-
albuminuria and from microalbuminuria to macroalbumi-
nuria in newly diagnosed patients with type 2 diabetes were
2% and 2.8% per year, respectively [4]. Ravid et al. [11]
reported higher progression rates in type 2 diabetic patients
in Israel, i.e. 35% from normoalbuminuria to microalbumi-
nuria and 16% from normoalbuminuria to macroalbuminu-
ria during 7.8 years. In Pima Indians with normotensive
type 2 diabetes, Nelson et al. [12] also reported that the
rates of progression from normoalbuminuria to micro-
albuminuria and to macroalbuminuria during 4.7 years
was 37.8% and 4.3%, respectively. In Japan, a clinic-based
observational 6.8 year longitudinal study of 426 patients
who developed diabetes before the age of 30 years revealed
that the incidence of proteinuria developing from normoal-
buminuria or microalbuminuria was 1.41/100 person-years
[13]. In another Japanese clinic-based observational longi-
tudinal study conducted for 6 years, 28% of 216 patients
enrolled from 1996 to 1998 showed progression from
microalbuminuria to proteinuria [14]. It is difficult to
compare the annual incidence of proteinuria with that
found in other studies because the stages of nephropathy
Basal UACR (mg/mmol) Final UACR (mg/mmol)
<3.4 3.4–17.0 17.0–33.9 ≥33.9
<3.4 817 (73.9) 244 (22.1) 27 (2.4) 18 (1.6)
3.4–17.0 137 (30.3) 203 (44.9) 56 (12.4) 56 (12.4)
Total 954 (61.2) 447 (28.7) 83 (5.3) 74 (4.8)
Table 3 Mean UACR measured
at the final two visits stratified
by the basal value
Data shown are n (%)
Variable Baseline 4 years after start
of intervention
8 years after start
of intervention
BMI (kg/m
2) 23.0±2.9 23.0±3.0 23.0±3.1
SBP (mmHg) 132.4±15.8 132.5±15.4 132.5±15.9
DBP (mmHg) 76.6±9.5 75.9±9.1 74.0±10.0
Fasting plasma glucose (mmol/l) 8.9±2.4 8.9±2.6 8.6±2.5
HbA1c (%) 7.8±1.3 7.7±1.2 7.7±2.0
Hypoglycaemic agent (%)
Any use 84.4 89.3 86.6
Insulin 20.7 30.1 41.9
Sulfonylurea 62.3 63.3 59.7
Alpha-glucosidase inhibitor 25.9 29.9 28.8
Biguanide 7.5 16.1 32.8
Insulin sensitiser 1.2 8.0 9.1
Antihypertensive agent (%)
Any use 28.2 33.3 42.0
ACE inhibitor/ARB 12.3 16.6 28.4
Calcium-channel blocker 20.7 24.4 27.2
Diuretic 1.2 1.1 2.9
Other 6.0 7.1 8.6
Statin (%) 20.5 23.7 31.1
Table 2 Measures of glycaemic
and blood pressure control at the
baseline and at 4 and 8 years
after the start of intervention
Each value is expressed as
mean ± SD or percentage
DBP, diastolic blood pressure
1028 Diabetologia (2011) 54:1025–1031differ from one study to another. However, the rate of
transition to proteinuria in the JDCS seems to be very low.
Of course, one of the reasons for this low incidence might
be that two-thirds of the enrolled patients had normoalbu-
minuria and one-third had low microalbuminuria. In
contrast, the placebo group in the INNOVATION trial
showed a considerably higher transition rate, amounting to
50%, from high microalbuminuria to proteinuria within
2 years, with a UACR between 11.3 and 33.9 mg/mmol [6],
although the UACR was determined using the first-voided
Risk factor Hazard ratio 95% CI p value
Conventional/intervention 1.01 0.63–1.61 0.98
Age, +10 years 1.03 0.71–1.49 0.87
Sex, woman/man 0.74 0.41–1.34 0.32
Duration, +10 years 1.16 0.80–1.68 0.44
BMI, +1 kg/m
2 1.01 0.93–1.10 0.73
SBP, 120–140/<120 mmHg 1.90 0.73–4.95 0.19
SBP, ≥140/<120 mmHg 2.55 0.98–6.63 0.05
HbA1c,7 –9/<7% 2.22 1.00–4.96 0.05
HbA1c, ≥9/<7% 4.16 1.73–10.04 <0.01
LDL-cholesterol, ≥4.0/<4.0 mmol/l 0.85 0.48–1.49 0.57
Triacylglycerol, ≥2.3/<2.3 mmol/l 1.60 0.88–2.89 0.12
HDL-cholesterol, ≥1.0/<1.0 mmol/l 1.43 0.79–2.61 0.24
UACR, ≥3.4/<3.4 mg/mmol 6.98 4.02–12.10 <0.01
Current smoker/past or never smoker 1.87 1.07–3.25 0.03
Ethanol intake, ≥38 g/<38 g/day 0.99 0.98–1.01 0.38
Table 4 Risk factors for
progression to proteinuria
demonstrated by multivariate
Cox regression analysis
Missing values meant 126
patients were excluded
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Fig. 1 Kaplan–Meier curves for
progression to overt nephropa-
thy according to: UACR (a),
HbA1c levels (b), SBP (c) and
smoking status (d). a The
hazard ratio for the low-
microalbuminuric group
(solid line) was 8.45 (95% CI
4.97–14.38, p<0.01) relative to
the normoalbuminuric group
(dashed–dotted line). b The
hazard ratio of HbA1c for a
range of 7–9% (solid line) and
for ≥9% (dotted line) was 2.72
(95% CI 1.22–6.03, p<0.01)
and 5.81 (95% CI 2.49–13.55,
p<0.01), respectively, relative to
an HbA1c of <7% (dashed–dot-
ted line). c The hazard ratio for
an SBP of 120–140 mmHg
(solid line) or ≥140 mmHg
(dotted line) was 2.31 (95% CI
0.96–5.54, p<0.06) and 3.54
(95% CI 1.50–8.40, p<0.01),
respectively, relative to an SBP
of <120 mmHg (dashed–dotted
line). d The hazard ratio for
current smoking (solid line)
was 1.99 (95% CI 1.24–3.18,
p<0.01) relative to past
smoking or never smoked
(dashed–dotted line)
Diabetologia (2011) 54:1025–1031 1029morning urine. Taken together with these studies, the data
suggest that the current treatment by diabetologists along
with administration of the usual hypoglycaemic and
hypotensive drugs from the stage of normoalbuminuria or
low microalbuminuria reduced the annual incidence of
proteinuria to a level as low as 0.67/100 person-years.
Ideally, however, the inclusion of a control group receiving
placebo and matched to the drug-treated diabetic patients
would be desirable in order to allow a firm conclusion to be
drawn, although admittedly this would be ethically prob-
lematic. As the baseline UACR profoundly affected the
cumulative incidence of proteinuria, it might be clinically
useful to divide patients with microalbuminuria into low-
and high-risk groups, i.e. those with low and high micro-
albuminuria, although the cut-off value remains to be
determined.
In the present study, progression to proteinuria was
independently associated with higher baseline HbA1c and
SBP levels in addition to an elevated baseline UACR.
Furthermore, smoking was also a significant predictor of
proteinuria. These results are consistent with previous
studies [11, 15]. In the UKPDS, the risk factors most
highly associated with proteinuria were reported to be
urinary albumin, plasma creatinine, waist circumference,
SBP, glycaemic control, LDL-cholesterol, and plasma
triacylglycerol [15]. Indian-Asian ethnicity was also an
independent risk factor for microalbuminuria and/or pro-
teinuria [12, 15]. Smoking and male sex were reported to be
independent predictors of proteinuria in addition to plasma
cholesterol, mean blood pressure and HbA1c [11]. Based on
these epidemiological studies, tight glycaemic control has
been reported to be effective for preventing the onset and/or
progression of nephropathy in clinical trials such as the
Diabetes Control and Complications Trial (DCCT), the
Kumamoto study and the UKPDS [16–18]. Strict blood
pressure control, especially with ACE inhibitors or ARBs,
has also been demonstrated to be effective for delaying the
progression of diabetic nephropathy [6, 7, 19–21]. Howev-
er, in the present study, the initial usage of an ACE inhibitor
and/or ARB, or statin was not significantly associated with
the prevention of proteinuria. As this study was designed to
clarify the effects of lifestyle intervention on subsequent
occurrence of diabetic complications, it might have been
difficult to recognise the effects of such drugs on the
progression of diabetic nephropathy. In some studies,
normalisation of microalbuminuria, i.e. remission/regres-
sion, has also been reported [6, 12]. In fact, in our study,
30.3% of 452 individuals with low microalbuminuria
demonstrated normalisation.
However, following the advent of modern therapeutics,
especially hypoglycaemic and antihypertensive agents,
diabetic nephropathy is the most common cause of ESRD,
and the number of patients being started on haemodialysis
is still increasing dramatically in many countries, particu-
larly in Asia. Our data have major clinical relevance
because we have demonstrated that the initiation of
hypoglycaemic and antihypertensive treatment from the
early stage of nephropathy might lower the rate of transition
to proteinuria even in the Japanese, who are highly
susceptible to diabetic nephropathy. To reduce the number
of patients who require haemodialysis, it is very important
to measure UACR, make a diagnosis of diabetic nephrop-
athy, define the stage of nephropathy and initiate strict
glycaemic and blood pressure control as early as at the
normo- or low-microalbuminuria stage.
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